Correlation of Tumor ARID1A Mutations, BRAF V600E Mutations and Microsatellite Instability in Sporadic and Tamoxifen-Associated High Grade Endometrial Cancer

Tamoxifen (TAM), a selective estrogen receptor modulator used in breast cancer therapy, has partial agonist activity on the endometrium and increases the risk for developing type II endometrial carcinomas. While the mechanism of TAM induced tumorigenesis is unknown, several genetic alterations have been identified in endometrial carcinoma. Recently, genetic instability in the hMLH1 gene has been linked to BRAF V600E …